<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656393</url>
  </required_header>
  <id_info>
    <org_study_id>SZLY2017024</org_study_id>
    <nct_id>NCT03656393</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma</brief_title>
  <acronym>RCTACSCNSCLC</acronym>
  <official_title>Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib
      versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib
      versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients. The purpose is to
      explore the role of TKI in neoadjuvant therapy, and to further improve disease-free survival
      (DFS) and pathologic complete remission (pCR) in EGFR-mutant populations; and reduce surgical
      complications and mortality.

      OBJECTIVES: To evaluate the efficacy of oral gefitinib versus neoadjuvant vinorelbine and
      carboplatin in operable stage II-IIIA EGFR-mutant non-squamous NSCLC patients, with a 2-year
      disease-free survival rate. 2yDFS).

      Secondary objective: To evaluate pCR, 0RR, and other efficacy measures (safety, complete) for
      oral gefitinib vs. neoadjuvant vinorelbine and carboplatin in patients with operable stage
      II-IIIA EGFR-mutant non-squamous cell carcinoma NSCLC. Resection rate, tumor regression,
      mediastinal lymph node clearance, perioperative complications, and mortality rate).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2y DFS</measure>
    <time_frame>2 years</time_frame>
    <description>2-year disease-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>objective response rates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>NSCLC</condition>
  <condition>EGFR</condition>
  <arm_group>
    <arm_group_label>Gefitinib therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinorelbine combination therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib (250 mg, orally, every day) for 56 days</description>
    <arm_group_label>Gefitinib therapy group</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks</description>
    <arm_group_label>Vinorelbine combination therapy group</arm_group_label>
    <other_name>5'-noranhydrovinblastine</other_name>
    <other_name>5-Nonylthio-8-methylthio-chinolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks</description>
    <arm_group_label>Vinorelbine combination therapy group</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Ercar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The pathological diagnosis is non-squamous cell carcinoma and non-small cell lung
             cancer. The pre-treatment tumor stage is stage II-IIIA;

          2. The gene detects EGFR mutations is positive;

          3. The age is between 18-70 years;

          4. ECOG 0-1;

          5. Liver and kidney function and Bone marrow hematopoiesis is normal;

          6. There are no serious systemic, respiratory, cardiovascular and other important
             systemic dysfunctions and severe malnutrition;

          7. No other malignant diseases within 5 years;

          8. Patients who have not received radiotherapy, systemic chemotherapy, or biological
             therapy;

          9. Understand the whole process of the trial and voluntarily participate in and sign the
             informed consent form.

        Exclusion Criteria:

          1. The tumor has invaded the surrounding tissue;

          2. Preoperative evidence suggests that distant metastases of the lesion include
             contralateral mediastinal lymph node metastasis;

          3. Arrhythmias require anti-arrhythmia therapy (Î²-blocker or digoxin Except), symptomatic
             coronary artery disease or myocardium. Ischemic or congestive heart failure exceeds
             NYHA class II;

          4. severe hypertension with poor drug control;

          5. moderate to severe proteinuria;

          6. HIV fluHistory of infection or active chronic hepatitis B or C;

          7. Malnutrition, decompensation of organ function;

          8. History of chest radiotherapy;

          9. Incomplete inflammation of eyes;

         10. Patients with seizures that need to be treated;

         11. Interstitial pneumonia;

         12. Drug abuse and others that may interfere with patients' participation in the study or
             studyThe assessment of the results has an impact;

         13. Allergies to the study drug are known or suspected to be allergic to or administered
             to any drug associated with this test;

         14. Any instability. The condition of the patient may jeopardize patient safety and
             compliance;

         15. Pregnancy or breastfeeding women and having fertility without adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Chen, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Shenzhen People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Lingwei, Doctor</last_name>
    <phone>15914030269</phone>
    <email>limey@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Guangsuo, Doctor</last_name>
    <phone>13590437796</phone>
    <email>908611104@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang wei, Doctor</last_name>
      <phone>15914030296</phone>
      <email>limey@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>wang suo, Doctor</last_name>
      <phone>13590437796</phone>
      <email>908611104@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>Gefitinib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

